Dr. Hashemi Sadraei Discusses Biomarkers in HPV-Induced Tumors

Nooshin Hashemi Sadraei, MD
Published: Thursday, Jul 30, 2015



Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Hashemi Sadraei discusses a recent study that examined 201 patients with anal cancer, 321 patients with cervical cancer, and 358 patients with oropharyngeal cancer. Researchers sought to determine if, since the tumor ideology of these three groups are similar, if molecular patterns exist among them. Next-generation sequencing, immunohistochemistry, and in situ hybridization were used to compare the presence of mutations, amplification, and protein expression among the three tumor types.

The study showed that there are significant similarities, Hashemi Sadraei says. Neither mutations or protein expressions were found to be statistically different among the three tumors. Moreover, similar levels of PD-1/PD-L1 expression were found. Due to these findings, researchers may be able to explore new therapeutic options that could elicit responses in all three subgroups, Hashemi Sadraei says.


Nooshin Hashemi Sadraei, MD, assistant professor of medicine, Department of Internal Medicine, University of Cincinnati, discusses biomarkers in HPV-induced tumors, including cervical, anal, and oropharyngeal cancers.

Hashemi Sadraei discusses a recent study that examined 201 patients with anal cancer, 321 patients with cervical cancer, and 358 patients with oropharyngeal cancer. Researchers sought to determine if, since the tumor ideology of these three groups are similar, if molecular patterns exist among them. Next-generation sequencing, immunohistochemistry, and in situ hybridization were used to compare the presence of mutations, amplification, and protein expression among the three tumor types.

The study showed that there are significant similarities, Hashemi Sadraei says. Neither mutations or protein expressions were found to be statistically different among the three tumors. Moreover, similar levels of PD-1/PD-L1 expression were found. Due to these findings, researchers may be able to explore new therapeutic options that could elicit responses in all three subgroups, Hashemi Sadraei says.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Oncology Best Practice™: Choosing Therapies for Patients with EGFR-mutant Lung Cancers: More Options... More Decisions... Better OutcomesApr 27, 20182.0
Community Practice Connections™: 21st Annual International Congress on Hematologic Malignancies®: Focus on Leukemias, Lymphomas, and MyelomaApr 27, 20182.0
Publication Bottom Border
Border Publication
x